Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JANET L DITTUS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecology

NPI
1104817667
CMS profile
321812
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$58.91

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $35.20 1
Food and Beverage $23.71 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
ASCEND THERAPEUTICS US, LLC $35.20 1
PFIZER INC. $23.71 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JANET L DITTUS

NPI 1104817667 · CMS profile ID 321812

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JANET L DITTUS, NPI 1104817667, CMS profile ID 321812. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JANET L DITTUS, NPI 1104817667, CMS profile ID 321812. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JANET L DITTUS, NPI 1104817667, CMS profile ID 321812, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $58.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.5804/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743176389 CMS
ASCEND THERAPEUTICS US, LLC $35.2002/13/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742114409 CMS
PFIZER INC. $12.1301/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743158617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $239.38 16
PY2020 $58.91 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $76,960.26 59
PY2024 Principal investigator $125,208.78 84
PY2023 Principal investigator $164,586.56 110
PY2022 Principal investigator $206,862.26 97
PY2021 Principal investigator $276,121.42 137
PY2020 Principal investigator $399,361.17 89
PY2019 Principal investigator $337,852.09 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $86.94 12/31/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 965539923
Principal investigator 1 ABBVIE INC. $90.00 12/28/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890369345
Principal investigator 1 ABBVIE INC. $99.77 12/28/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890370073
Principal investigator 1 ABBVIE INC. $100.00 12/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890369349
Principal investigator 1 ABBVIE INC. $580.00 12/08/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890370071
Principal investigator 1 ABBVIE INC. $4,076.25 12/08/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890370075
Principal investigator 1 ABBVIE INC. $315.00 12/02/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890370067
Principal investigator 1 ABBVIE INC. $2,406.88 12/01/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890369347
Principal investigator 1 ABBVIE INC. $33.25 12/01/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890370069
Principal investigator 1 ABBVIE INC. $33.23 11/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889821825
Principal investigator 1 ABBVIE INC. $430.00 11/17/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889821409
Principal investigator 1 ABBVIE INC. $580.00 11/17/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368611
Principal investigator 1 ABBVIE INC. $33.23 11/09/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368613
Principal investigator 1 ABBVIE INC. $7,738.75 11/08/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368749
Principal investigator 1 ABBVIE INC. $9.35 11/03/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889818103
Principal investigator 1 ABBVIE INC. $100.00 11/03/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368615
Principal investigator 1 ABBVIE INC. $2,406.88 11/03/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368617
Principal investigator 1 ABBVIE INC. $2,406.88 10/27/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368619
Principal investigator 1 ABBVIE INC. $2,800.03 10/26/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889817357
Principal investigator 1 ABBVIE INC. $49.84 10/20/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368537
Principal investigator 1 ABBVIE INC. $3,575.63 10/13/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368753
Principal investigator 1 ABBVIE INC. $781.25 10/06/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889813441
Principal investigator 1 ABBVIE INC. $19.95 10/06/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368475
Principal investigator 1 ABBVIE INC. $100.00 10/06/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368477
Principal investigator 1 ABBVIE INC. $8,233.13 10/06/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890368751
Principal investigator 1 ABBVIE INC. $100.00 10/05/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889813065
Principal investigator 1 ABBVIE INC. $41.87 09/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367291
Principal investigator 1 ABBVIE INC. $3,575.63 09/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367293
Principal investigator 1 ABBVIE INC. $567.50 09/22/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367233
Principal investigator 1 ABBVIE INC. $83.74 09/22/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367289
Principal investigator 1 ABBVIE INC. $1,135.00 09/15/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367231
Principal investigator 1 ABBVIE INC. $4,675.00 09/08/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367229
Principal investigator 1 ABBVIE INC. $100.00 09/01/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367287
Principal investigator 1 ABBVIE INC. $572.50 08/25/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367127
Principal investigator 1 ABBVIE INC. $3,008.13 08/22/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890366719
Principal investigator 1 ABBVIE INC. $3,575.63 08/22/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367285
Principal investigator 1 ABBVIE INC. $392.50 08/19/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367129
Principal investigator 1 ABBVIE INC. $3,575.63 08/18/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367125
Principal investigator 1 ABBVIE INC. $567.50 08/18/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367225
Principal investigator 1 ABBVIE INC. $8,825.00 08/11/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890367227
Principal investigator 1 ABBVIE INC. $100.00 08/01/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889802887
Principal investigator 1 ABBVIE INC. $135.00 07/29/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889802695
Principal investigator 1 ABBVIE INC. $16,305.03 07/28/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889802525
Principal investigator 1 ABBVIE INC. $6.11 07/26/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364921
Principal investigator 1 ABBVIE INC. $83.57 07/21/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889801751
Principal investigator 1 ABBVIE INC. $78.21 07/18/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364865
Principal investigator 1 ABBVIE INC. $918.00 07/15/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364907
Principal investigator 1 ABBVIE INC. $2,883.75 07/12/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364919
Principal investigator 1 ABBVIE INC. $100.00 07/07/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889798643
Principal investigator 1 ABBVIE INC. $135.00 07/07/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889798659
Principal investigator 1 ABBVIE INC. $580.00 07/04/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890365407
Principal investigator 1 ABBVIE INC. $51.99 06/27/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364049
Principal investigator 1 ABBVIE INC. $135.00 06/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889797005
Principal investigator 1 ABBVIE INC. $135.00 06/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889797039
Principal investigator 1 ABBVIE INC. $83.57 06/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889797057
Principal investigator 1 ABBVIE INC. $358.75 06/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889797061
Principal investigator 1 ABBVIE INC. $52.00 06/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889797063
Principal investigator 1 ABBVIE INC. $135.00 06/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889797065
Principal investigator 1 ABBVIE INC. $66.10 06/22/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364287
Principal investigator 1 ABBVIE INC. $7,770.00 06/09/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364059
Principal investigator 1 ABBVIE INC. $7,535.65 06/08/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889794325
Principal investigator 1 ABBVIE INC. $11.30 06/02/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364051
Principal investigator 1 ABBVIE INC. $358.75 05/26/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889792941
Principal investigator 1 ABBVIE INC. $135.00 05/26/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889792943
Principal investigator 1 ABBVIE INC. $358.75 05/26/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889792945
Principal investigator 1 ABBVIE INC. $100.00 05/26/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364053
Principal investigator 1 ABBVIE INC. $72.69 05/19/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890363773
Principal investigator 1 ABBVIE INC. $7,637.55 05/05/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889790337
Principal investigator 1 ABBVIE INC. $6,388.75 05/05/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890364061
Principal investigator 1 ABBVIE INC. $1,562.50 05/02/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889789149
Principal investigator 1 ABBVIE INC. $100.00 04/25/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889788563
Principal investigator 1 ABBVIE INC. $16.32 04/18/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890362385
Principal investigator 1 ABBVIE INC. $72.21 04/13/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890362387
Principal investigator 1 ABBVIE INC. $9,718.80 04/07/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889784275
Principal investigator 1 ABBVIE INC. $6,078.75 04/07/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890362383
Principal investigator 1 ABBVIE INC. $20.00 04/07/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890362389
Principal investigator 1 ABBVIE INC. $2,316.88 03/31/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361653
Principal investigator 1 ABBVIE INC. $90.00 03/31/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361759
Principal investigator 1 ABBVIE INC. $70.13 03/30/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361665
Principal investigator 1 ABBVIE INC. $100.00 03/23/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889782365
Principal investigator 1 ABBVIE INC. $16.41 03/17/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361667
Principal investigator 1 ABBVIE INC. $13,899.38 03/17/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361757
Principal investigator 1 ABBVIE INC. $252.50 03/15/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889781077
Principal investigator 1 ABBVIE INC. $80.00 03/10/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361655
Principal investigator 1 ABBVIE INC. $202.50 03/02/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361661
Principal investigator 1 ABBVIE INC. $90.00 03/01/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361657
Principal investigator 1 ABBVIE INC. $3,485.63 03/01/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890361659
Principal investigator 1 ABBVIE INC. $11,606.28 02/24/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889778461
Principal investigator 1 ABBVIE INC. $13,210.06 02/16/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889777445
Principal investigator 1 ABBVIE INC. $8,535.00 02/15/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 889777041
Principal investigator 1 ABBVIE INC. $100.00 02/14/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889776963
Principal investigator 1 ABBVIE INC. $651.25 02/14/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889776967
Principal investigator 1 ABBVIE INC. $90.00 02/10/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 889776495
Principal investigator 1 ABBVIE INC. $70.13 02/10/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889776611
Principal investigator 1 ABBVIE INC. $3,575.63 02/03/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 889775395
Principal investigator 1 ABBVIE INC. $70.13 02/01/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 889775151
Principal investigator 1 ABBVIE INC. $10,189.38 01/12/2022 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 889773243